Q4 2025 Management View CEO Dikla Akselbrad described 2025 as “a pivotal year for PolyPid,” highlighting the completion of ...

Candidates appearing for the Civil Services Examination (CSE) 2026 will get an opportunity to make changes to their ...

PolyPid (NASDAQ:PYPD) said 2025 marked a “pivotal year” as the company completed its SHIELD II Phase 3 trial and moved D-PLEX100 into the final stages of regulatory preparation, while also advancing U ...

For the twelve months ended December 31, 2025, the Company had a net loss of $34.2 million, or ($2.09) per share, compared to a net loss of $29.0 million, or ($4.91) per share, in the twelve-month ...

Both of NDA's routines, for the first time in school history, advanced to Finals while St. Joseph Hill earned a spot for the ...

In a fiery retort, Rabri Devi, the opposition face of Bihar, leveled strong allegations against the NDA, claiming they ...

The Company is in Advanced Stages of Commercial U.S. Partnership Discussions for D-PLEX100 Positive FDA Pre-NDA Feedback Supports Rolling NDA Review- Submission Expected to Begin by the End of the Fir ...

UPSC released NDA & NA (I) 2026 exam date: 12 April 2026. Notification released 10 Dec 2025; apply by 30 Dec 2025. NDA & NA (II) exam tentatively scheduled for 13 September 2026. UPSC NDA Exam Date ...

The PM, it is learnt, also said that the biggest realignment since World War II is now underway and it is bringing India to ...

NDA made program history as both its Traditional and Game-Day teams made it into Finals while the Hilltoppers have hit their ...

KalVista Pharmaceuticals, Inc. is rated a Strong Buy due to EKTERLY's global launch and robust initial sales momentum. Read ...